DNBC-FINANCIAL-GROUP
13.4.2022 11:24:09 CEST | Business Wire | Press release
Sending money abroad has traditionally been an arduous and expensive task that frustrates users. Plus with the post-pandemic changes, people now need a faster yet cheaper contactless money transfer solution that can be done quickly on a mobile. That leads to the demand for payment apps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005433/en/
But which ones are the best international payment apps ? That depends. The best payment apps are the ones that work best for your business.
DNBCnet App - Powered by the leading Digital Banking Firm DNBC
Digital banking firm DNBC was founded by Le Hung Anh in 2017, professionally known as Jimmy Lee, headquartered in Singapore.
With the mission to support enterprises as well as individuals in financial transactions over the world, DNBC has developed the DNBCnet app in order to make the banking process easier yet cheaper by adapting more innovative changes right on the app.
“DNBCnet is an all-in-one tool for any user who wants to conduct international transactions, manage and control the cash flow of their business,” said Jimmy Lee, Founder & CEO of DNBC.
DNBCnet App offers exceptional benefits
Best for corporate international money transfers
When it comes to international payments , companies just want to make quick transactions while keeping the costs as low as possible.
It can be difficult to find a provider that offers quick transfers and low fees. But if you want to keep your business straightforward, you don’t have to look very far because DNBC business accounts will fit the bill.
“If you structure payments properly, digital banking can create more predictable cash flow over the life of your business,” said CEO Jimmy Lee.
Fastest ways to send money abroad
When sending money globally, an important factor besides fees is the speed. Speedy transfer will accelerate the business, otherwise it will slow down the whole operation significantly.
With DNBCnet app , recipients will get the fund instantly if transferred in DNBC network. It only takes 1-2 business days to send to someone outside the system.
Ease of use
DNBCnet works as a mobile app, the signing up process can be done quickly with a few simple steps. It owns a seamless visual interface which allows users to handle payments in no time.
On top of that, you can keep track of your transfer and get updates along the way, so you’re always in the loop about your funds.
Utmost safety for mobile banking
Security is a must for any financial app . DNBC has raised its standard by adopting the latest technology such as two-factor authentication , data encryption for every transaction.
That will help protect account information and transactions to the fullest extent preventing any potential frauds for customers and businesses.
As a bonus perk
Besides the core function, DNBCnet also adds up a number of accompanying features to make it even more favorable. Users now can also check real-time exchange rate information, view financial statistics by charts, send mobile top up and many more.
Level up your payment practice with DNBCnet app
One of the key benefits of digital banking apps is that they allow users to manage payments anywhere and anytime. With that, business owners can focus on delivering services, not bothering with the payment process .
DNBCnet app offers exceptional convenience and transparency to its users. Via smartphones, you can find the IOS version for mobile banking on the App Store or mobile banking app for Android in the Google Store. Or simply search for DNBCnet .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005433/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom